Advanced Search

Project: Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Entered Retrospectively]

Public Report Complete



Project Summary

Title and Description


Key Questions


Associated Extraction Forms

Title Created by Key Questions Addressed Form Notes
Key Questions 1-5 Sara Grusing 1, 2, 3, 4, 5


Associated Studies (each link opens a new tab)

Title Author Year
Predictors of and satisfaction with bilateral prophylactic mastectomy. Stefanek ME., Helzlsouer KJ., Wilcox PM., Houn F. 1995
Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. Bourne TH., Campbell S., Reynolds KM., Whitehead MI., Hampson J., Royston P., Crayford TJ., Collins WP. 1993
Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy. Metcalfe KA., Esplen MJ., Goel V., Narod SA. 2004
Impact of screening for breast cancer in high-risk women on health-related quality of life. Rijnsburger AJ., Essink-Bot ML., van Dooren S., Borsboom GJ., Seynaeve C., Bartels CC., Klijn JG., Tibben A., de Koning HJ. 2004
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. Kriege M., Brekelmans CT., Boetes C., Besnard PE., Zonderland HM., Obdeijn IM., Manoliu RA., Kok T., Peterse H., Tilanus-Linthorst MM., Muller SH., Meijer S., Oosterwijk JC., Beex LV., Tollenaar RA., de Koning HJ., Rutgers EJ., Klijn JG. 2004
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Leach MO., Boggis CR., Dixon AK., Easton DF., Eeles RA., Evans DG., Gilbert FJ., Griebsch I., Hoff RJ., Kessar P., Lakhani SR., Moss SM., Nerurkar A., Padhani AR., Pointon LJ., Thompson D., Warren RM. -- Not Found --
Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition. Kriege M., Brekelmans CT., Boetes C., Muller SH., Zonderland HM., Obdeijn IM., Manoliu RA., Kok T., Rutgers EJ., de Koning HJ., Klijn JG. 2006
The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomy. Bresser PJ., Seynaeve C., Van Gool AR., Niermeijer MF., Duivenvoorden HJ., van Dooren S., van Geel AN., Menke-Pluijmers MB., Klijn JG., Tibben A. 2007
No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Hermsen BB., Olivier RI., Verheijen RH., van Beurden M., de Hullu JA., Massuger LF., Burger CW., Brekelmans CT., Mourits MJ., de Bock GH., Gaarenstroom KN., van Boven HH., Mooij TM., Rookus MA. 2007
Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Heemskerk-Gerritsen BA., Brekelmans CT., Menke-Pluymers MB., van Geel AN., Tilanus-Linthorst MM., Bartels CC., Tan M., Meijers-Heijboer HE., Klijn JG., Seynaeve C. 2007
Aesthetic outcome, patient satisfaction, and health-related quality of life in women at high risk undergoing prophylactic mastectomy and immediate breast reconstruction. Isern AE., Tengrup I., Loman N., Olsson H., Ringberg A. 2008
Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. Brandberg Y., Sandelin K., Erikson S., Jurell G., Liljegren A., Lindblom A., Lindén A., von Wachenfeldt A., Wickman M., Arver B. 2008
Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer. Michelsen TM., Dørum A., Tropé CG., Fosså SD., Dahl AA. 2009
Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. Kenkhuis MJ., de Bock GH., Elferink PO., Arts HJ., Oosterwijk JC., Jansen L., Mourits MJ. 2010
High satisfaction rate ten years after bilateral prophylactic mastectomy - a longitudinal study. Wasteson E., Sandelin K., Brandberg Y., Wickman M., Arver B. 2011
Bilateral prophylactic mastectomy in women with inherited risk of breast cancer--prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery. Gahm J., Wickman M., Brandberg Y. 2010
The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Finch A., Metcalfe KA., Chiang JK., Elit L., McLaughlin J., Springate C., Demsky R., Murphy J., Rosen B., Narod SA. 2011
Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Le-Petross HT., Whitman GJ., Atchley DP., Yuan Y., Gutierrez-Barrera A., Hortobagyi GN., Litton JK., Arun BK. 2011
Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey. Arver B., Isaksson K., Atterhem H., Baan A., Bergkvist L., Brandberg Y., Ehrencrona H., Emanuelsson M., Hellborg H., Henriksson K., Karlsson P., Loman N., Lundberg J., Ringberg A., Askmalm MS., Wickman M., Sandelin K. 2011
Psychological impact of recall on women with BRCA mutations undergoing MRI surveillance. Spiegel TN., Esplen MJ., Hill KA., Wong J., Causer PA., Warner E. 2011
Less correspondence between expectations before and cosmetic results after risk-reducing mastectomy in women who are mutation carriers: a prospective study. Brandberg Y., Arver B., Johansson H., Wickman M., Sandelin K., Liljegren A. 2012
Body image and psychological distress after prophylactic mastectomy and breast reconstruction in genetically predisposed women: a prospective long-term follow-up study. den Heijer M., Seynaeve C., Timman R., Duivenvoorden HJ., Vanheusden K., Tilanus-Linthorst M., Menke-Pluijmers MB., Tibben A. 2012
Long-term psychological distress in women at risk for hereditary breast cancer adhering to regular surveillance: a risk profile. den Heijer M., Seynaeve C., Vanheusden K., Timman R., Duivenvoorden HJ., Tilanus-Linthorst M., Menke-Pluijmers MB., Tibben A. 2013
Body image issues after bilateral prophylactic mastectomy with breast reconstruction in healthy women at risk for hereditary breast cancer. Gopie JP., Mureau MA., Seynaeve C., Ter Kuile MM., Menke-Pluymers MB., Timman R., Tibben A. 2013
The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers. Borreani C., Manoukian S., Bianchi E., Brunelli C., Peissel B., Caruso A., Morasso G., Pierotti MA. 2014
Effects of false-positive cancer screenings and cancer worry on risk-reducing surgery among BRCA1/2 carriers. Portnoy DB., Loud JT., Han PK., Mai PL., Greene MH. 2015
Patient experience with breast reconstruction process following bilateral mastectomy in BRCA mutation carriers. Nurudeen S., Guo H., Chun Y., Coopey S., Barry W., Garber J., Dominici LS. 2017
Multidisciplinary management of risk-reducing mastectomy and immediate reconstruction: treatment algorithm and patient satisfaction Alamouti, R. Hachach-Haram, N. Farhadi, J. 2015
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Domchek SM., Friebel TM., Singer CF., Evans DG., Lynch HT., Isaacs C., Garber JE., Neuhausen SL., Matloff E., Eeles R., Pichert G., Van t'veer L., Tung N., Weitzel JN., Couch FJ., Rubinstein WS., Ganz PA., Daly MB., Olopade OI., Tomlinson G., Schildkraut J., Blum JL., Rebbeck TR. 2010
Risk reducing mastectomy: outcomes in 10 European centres. Evans DG., Baildam AD., Anderson E., Brain A., Shenton A., Vasen HF., Eccles D., Lucassen A., Pichert G., Hamed H., Moller P., Maehle L., Morrison PJ., Stoppat-Lyonnet D., Gregory H., Smyth E., Niederacher D., Nestle-Krämling C., Campbell J., Hopwood P., Lalloo F., Howell A. 2009
Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. Hartmann LC., Schaid DJ., Woods JE., Crotty TP., Myers JL., Arnold PG., Petty PM., Sellers TA., Johnson JL., McDonnell SK., Frost MH., Jenkins RB. 1999
Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. Hartmann LC., Sellers TA., Schaid DJ., Frank TS., Soderberg CL., Sitta DL., Frost MH., Grant CS., Donohue JH., Woods JE., McDonnell SK., Vockley CW., Deffenbaugh A., Couch FJ., Jenkins RB. 2001
Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. Kramer JL., Velazquez IA., Chen BE., Rosenberg PS., Struewing JP., Greene MH. 2005
Bilateral oophorectomy and breast cancer risk reduction among women with a family history. Olson JE., Sellers TA., Iturria SJ., Hartmann LC. 2004
Breast cancer after bilateral risk-reducing mastectomy. Skytte AB., Crüger D., Gerster M., Laenkholm AV., Lang C., Brøndum-Nielsen K., Andersen MK., Sunde L., Kølvraa S., Gerdes AM. 2011
Prophylactic oophorectomy in inherited breast/ovarian cancer families. Struewing JP., Watson P., Easton DF., Ponder BA., Lynch HT., Tucker MA. 1995
Surgical Decision Making in the BRCA-Positive Population: Institutional Experience and Comparison with Recent Literature. Flippo-Morton T., Walsh K., Chambers K., Amacker-North L., White B., Sarantou T., Boselli DM., White RL. -- Not Found --
Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. Heemskerk-Gerritsen BA., Seynaeve C., van Asperen CJ., Ausems MG., Collée JM., van Doorn HC., Gomez Garcia EB., Kets CM., van Leeuwen FE., Meijers-Heijboer HE., Mourits MJ., van Os TA., Vasen HF., Verhoef S., Rookus MA., Hooning MJ. 2015
Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Heemskerk-Gerritsen BA., Menke-Pluijmers MB., Jager A., Tilanus-Linthorst MM., Koppert LB., Obdeijn IM., van Deurzen CH., Collée JM., Seynaeve C., Hooning MJ. 2013
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. Mavaddat N., Peock S., Frost D., Ellis S., Platte R., Fineberg E., Evans DG., Izatt L., Eeles RA., Adlard J., Davidson R., Eccles D., Cole T., Cook J., Brewer C., Tischkowitz M., Douglas F., Hodgson S., Walker L., Porteous ME., Morrison PJ., Side LE., Kennedy MJ., Houghton C., Donaldson A., Rogers MT., Dorkins H., Miedzybrodzka Z., Gregory H., Eason J., Barwell J., McCann E., Murray A., Antoniou AC., Easton DF. 2013
Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence. Shah P., Rosen M., Stopfer J., Siegfried J., Kaltman R., Mason B., Armstrong K., Nathanson KL., Schnall M., Domchek SM. 2009
Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Kotsopoulos J., Huzarski T., Gronwald J., Singer CF., Moller P., Lynch HT., Armel S., Karlan B., Foulkes WD., Neuhausen SL., Senter L., Tung N., Weitzel JN., Eisen A., Metcalfe K., Eng C., Pal T., Evans G., Sun P., Lubinski J., Narod SA. 2017
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. Rebbeck TR., Lynch HT., Neuhausen SL., Narod SA., Van't Veer L., Garber JE., Evans G., Isaacs C., Daly MB., Matloff E., Olopade OI., Weber BL. 2002
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. Antoniou AC., Hardy R., Walker L., Evans DG., Shenton A., Eeles R., Shanley S., Pichert G., Izatt L., Rose S., Douglas F., Eccles D., Morrison PJ., Scott J., Zimmern RL., Easton DF., Pharoah PD. 2008
Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care. Ashton-Prolla P., Giacomazzi J., Schmidt AV., Roth FL., Palmero EI., Kalakun L., Aguiar ES., Moreira SM., Batassini E., Belo-Reyes V., Schuler-Faccini L., Giugliani R., Caleffi M., Camey SA. 2009
Assessing BRCA carrier probabilities in extended families. Barcenas CH., Hosain GM., Arun B., Zong J., Zhou X., Chen J., Cortada JM., Mills GB., Tomlinson GE., Miller AR., Strong LC., Amos CI. 2006
Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. Hoskins KF., Zwaagstra A., Ranz M. 2006
Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. Oros KK., Ghadirian P., Maugard CM., Perret C., Paredes Y., Mes-Masson AM., Foulkes WD., Provencher D., Tonin PN. 2006
Selecting a BRCA risk assessment model for use in a familial cancer clinic. Panchal SM., Ennis M., Canon S., Bordeleau LJ. 2008
A two-stage approach to genetic risk assessment in primary care. Biswas S., Atienza P., Chipman J., Blackford AL., Arun B., Hughes K., Parmigiani G. 2016
Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. Fischer C., Kuchenbäcker K., Engel C., Zachariae S., Rhiem K., Meindl A., Rahner N., Dikow N., Plendl H., Debatin I., Grimm T., Gadzicki D., Flöttmann R., Horvath J., Schröck E., Stock F., Schäfer D., Schwaab I., Kartsonaki C., Mavaddat N., Schlegelberger B., Antoniou AC., Schmutzler R. 2013
Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer. Kast K., Schmutzler RK., Rhiem K., Kiechle M., Fischer C., Niederacher D., Arnold N., Grimm T., Speiser D., Schlegelberger B., Varga D., Horvath J., Beer M., Briest S., Meindl A., Engel C. 2014
Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations. Teller P., Hoskins KF., Zwaagstra A., Stanislaw C., Iyengar R., Green VL., Gabram SG. 2010
Validity of models for predicting BRCA1 and BRCA2 mutations. Parmigiani G., Chen S., Iversen ES., Friebel TM., Finkelstein DM., Anton-Culver H., Ziogas A., Weber BL., Eisen A., Malone KE., Daling JR., Hsu L., Ostrander EA., Peterson LE., Schildkraut JM., Isaacs C., Corio C., Leondaridis L., Tomlinson G., Amos CI., Strong LC., Berry DA., Weitzel JN., Sand S., Dutson D., Kerber R., Peshkin BN., Euhus DM. 2007
A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Gilpin CA., Carson N., Hunter AG. 2000
A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. Evans DG., Eccles DM., Rahman N., Young K., Bulman M., Amir E., Shenton A., Howell A., Lalloo F. 2004
Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Bellcross CA., Lemke AA., Pape LS., Tess AL., Meisner LT. 2009
Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. Armstrong K., Micco E., Carney A., Stopfer J., Putt M. 2005
Psychological factors associated with emotional responses to receiving genetic risk information. Bennett P., Wilkinson C., Turner J., Brain K., Edwards RT., Griffith G., France B., Gray J. 2008
Factors associated with intrusive cancer-related worries in women undergoing cancer genetic risk assessment. Bennett P., Wilkinson C., Turner J., Edwards RT., France B., Griffith G., Griffin G., Gray J. 2009
Effects of a telephone counseling intervention on sisters of young women with breast cancer. Bloom JR., Stewart SL., Chang S., You M. 2006
Effects of counseling Ashkenazi Jewish women about breast cancer risk. Bowen DJ., Burke W., Culver JO., Press N., Crystal S. 2006
A randomized trial of specialist genetic assessment: psychological impact on women at different levels of familial breast cancer risk. Brain K., Norman P., Gray J., Rogers C., Mansel R., Harper P. 2002
The evolution of worry after breast cancer risk assessment: 6-year follow-up of the TRACE study cohort. Brain K., Parsons E., Bennett P., Cannings-John R., Hood K. 2011
Development of a risk assessment tool for women with a family history of breast cancer. Braithwaite D., Sutton S., Mackay J., Stein J., Emery J. 2005
A randomised controlled trial of breast cancer genetics services in South East Scotland: psychological impact. Fry A., Cull A., Appleton S., Rush R., Holloway S., Gorman D., Cetnarskyj R., Thomas R., Campbell J., Anderson E., Steel M., Porteous M., Campbell H. 2003
Patients' resistance to risk information in genetic counseling for BRCA1/2. Gurmankin AD., Domchek S., Stopfer J., Fels C., Armstrong K. 2005
Results of a randomized study of telephone versus in-person breast cancer risk counseling. Helmes AW., Culver JO., Bowen DJ. 2006
Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. Hopwood P., Keeling F., Long A., Pool C., Evans G., Howell A. -- Not Found --
A randomised comparison of UK genetic risk counselling services for familial cancer: psychosocial outcomes. Hopwood P., Wonderling D., Watson M., Cull A., Douglas F., Cole T., Eccles D., Gray J., Murday V., Steel M., Burn J., McPherson K. 2004
Subjective and objective risk of ovarian cancer in Ashkenazi Jewish women testing for BRCA1/2 mutations. Kelly KM., Senter L., Leventhal H., Ozakinci G., Porter K. 2008
A randomized trial of breast cancer risk counseling: interacting effects of counseling, educational level, and coping style. Lerman C., Schwartz MD., Miller SM., Daly M., Sands C., Rimer BK. 1996
Communication and information-giving in high-risk breast cancer consultations: influence on patient outcomes. Lobb EA., Butow PN., Barratt A., Meiser B., Gaff C., Young MA., Haan E., Suthers G., Gattas M., Tucker K. 2004
Healthy women with a family history of breast cancer: impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal therapy decision making. Matloff ET., Moyer A., Shannon KM., Niendorf KB., Col NF. 2006
Risk perception among women receiving genetic counseling: a population-based follow-up study. Mikkelsen EM., Sunde L., Johansen C., Johnsen SP. 2007
Psychosocial consequences of genetic counseling: a population-based follow-up study. Mikkelsen EM., Sunde L., Johansen C., Johnsen SP. -- Not Found --
Longer-term influence of breast cancer genetic counseling on cognitions and distress: smaller benefits for affected versus unaffected women. Pieterse AH., Ausems MG., Spreeuwenberg P., van Dulmen S. 2011
Does enhanced information at cancer genetic counseling improve counselees' knowledge, risk perception, satisfaction and negotiation of information to at-risk relatives?--a randomized study. Roshanai AH., Rosenquist R., Lampic C., Nordin K. 2009
A systematic review of the impact of genetic counseling on risk perception accuracy. Smerecnik CM., Mesters I., Verweij E., de Vries NK., de Vries H. 2009
Family history of breast cancer: what do women understand and recall about their genetic risk? Watson M., Duvivier V., Wade Walsh M., Ashley S., Davidson J., Papaikonomou M., Murday V., Sacks N., Eeles R. 1998
The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer. Watson M., Lloyd S., Davidson J., Meyer L., Eeles R., Ebbs S., Murday V. 1999
The use of videotaped information in cancer genetic counselling: a randomized evaluation study. Cull A., Miller H., Porterfield T., Mackay J., Anderson ED., Steel CM., Elton RA. 1998
Genetic counseling for women with an intermediate family history of breast cancer. Burke W., Culver JO., Bowen D., Lowry D., Durfy S., McTiernan A., Andersen MR. 2000
Effects of risk counseling on interest in breast cancer genetic testing for lower risk women. Bowen DJ., Burke W., Yasui Y., McTiernan A., McLeran D. -- Not Found --
Racial differences in testing motivation and psychological distress following pretest education for BRCA1 gene testing. Lerman C., Hughes C., Benkendorf JL., Biesecker B., Kerner J., Willison J., Eads N., Hadley D., Lynch J. 1999
Breast cancer risk counseling improves women's functioning. Bowen DJ., Burke W., McTiernan A., Yasui Y., Andersen MR. 2004
Counselees' Expressed Level of Understanding of the Risk Estimate and Surveillance Recommendation are Not Associated with Breast Cancer Surveillance Adherence. Albada A., van Dulmen S., Dijkstra H., Wieffer I., Witkamp A., Ausems MG. 2016
Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. Manchanda R., Loggenberg K., Sanderson S., Burnell M., Wardle J., Gessler S., Side L., Balogun N., Desai R., Kumar A., Dorkins H., Wallis Y., Chapman C., Taylor R., Jacobs C., Tomlinson I., McGuire A., Beller U., Menon U., Jacobs I. 2015
Evaluation of psychosocial effects of pre-symptomatic testing for breast/ovarian and colon cancer pre-disposing genes: a 12-month follow-up. Arver B., Haegermark A., Platten U., Lindblom A., Brandberg Y. 2004
Quality of life in asymptomatic BRCA1/2 mutation carriers. Dagan E., Shochat T. 2009
Identification of patients at high risk of psychological distress after BRCA1 genetic testing. Ertmański S., Metcalfe K., Trempała J., Głowacka MD., Lubiński J., Narod SA., Gronwald J. 2009
Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. Foster C., Watson M., Eeles R., Eccles D., Ashley S., Davidson R., Mackay J., Morrison PJ., Hopwood P., Evans DG. 2007
The relationship between coping strategies and anxiety in women from families with familial breast-ovarian cancer in the absence of demonstrated mutations. Geirdal AØ., Dahl AA. 2008
Psychological distress in women at risk of hereditary breast/ovarian or HNPCC cancers in the absence of demonstrated mutations. Geirdal AØ., Reichelt JG., Dahl AA., Heimdal K., Maehle L., Stormorken A., Møller P. 2005
Long-term psychosocial outcomes of BRCA1/BRCA2 testing: differences across affected status and risk-reducing surgery choice. Graves KD., Vegella P., Poggi EA., Peshkin BN., Tong A., Isaacs C., Finch C., Kelly S., Taylor KL., Luta G., Schwartz MD. 2012
Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations. Julian-Reynier C., Mancini J., Mouret-Fourme E., Gauthier-Villars M., Bonadona V., Berthet P., Fricker JP., Caron O., Luporsi E., Noguès C. 2011
The impact of receiving genetic test results on general and cancer-specific psychologic distress among members of an African-American kindred with a BRCA1 mutation. Kinney AY., Bloor LE., Mandal D., Simonsen SE., Baty BJ., Holubkov R., Seggar K., Neuhausen S., Smith K. 2005
Benefit finding in response to BRCA1/2 testing. Low CA., Bower JE., Kwan L., Seldon J. 2008
Psychological impact of genetic testing in women from high-risk breast cancer families. Meiser B., Butow P., Friedlander M., Barratt A., Schnieden V., Watson M., Brown J., Tucker K. 2002
Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening. Metcalfe KA., Mian N., Enmore M., Poll A., Llacuachaqui M., Nanda S., Sun P., Hughes KS., Narod SA. 2012
BRCA1 testing with definitive results: a prospective study of psychological distress in a large clinic-based sample. Reichelt JG., Heimdal K., Møller P., Dahl AA. 2004
Psychological and cancer-specific distress at 18 months post-testing in women with demonstrated BRCA1 mutations for hereditary breast/ovarian cancer. Reichelt JG., Møller P., Heimdal K., Dahl AA. 2008
Sleep disturbances in asymptomatic BRCA1/2 mutation carriers: women at high risk for breast-ovarian cancer. Shochat T., Dagan E. 2010
Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer. van Dijk S., Timmermans DR., Meijers-Heijboer H., Tibben A., van Asperen CJ., Otten W. 2006
Factors associated with an individual's decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling. Godard B., Pratte A., Dumont M., Simard-Lebrun A., Simard J. 2007
Psychological impact of genetic testing for breast cancer susceptibility in women of Ashkenazi Jewish background: a prospective study. Andrews L., Meiser B., Apicella C., Tucker K. 2004
Familial context of genetic testing for cancer susceptibility: moderating effect of siblings' test results on psychological distress one to two weeks after BRCA1 mutation testing. Smith KR., West JA., Croyle RT., Botkin JR. 1999
Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral. Lieberman S., Tomer A., Ben-Chetrit A., Olsha O., Strano S., Beeri R., Koka S., Fridman H., Djemal K., Glick I., Zalut T., Segev S., Sklair M., Kaufman B., Lahad A., Raz A., Levy-Lahad E. 2017
Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. van Oostrom I., Meijers-Heijboer H., Lodder LN., Duivenvoorden HJ., van Gool AR., Seynaeve C., van der Meer CA., Klijn JG., van Geel BN., Burger CW., Wladimiroff JW., Tibben A. 2003
Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients. Lumish HS., Steinfeld H., Koval C., Russo D., Levinson E., Wynn J., Duong J., Chung WK. 2017




Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: https://creativecommons.org/licenses/by-nc/3.0/